Search Results
Nikander, R., Sievänen, H., Heinonen, A. és mtsai: Targeted exercise against osteoporosis: A systematic review and meta-analysis for optimising bone strength throughout life. BMC Med., 2010, 8 , 47
: Epidemiology of osteoporosis related fractures in Hungary from the nationwide health insurance database, 1999–2003. Osteoporos. Int., 2008, 19 , 243–249. Boncz I. Epidemiology of
Kanis, J. A.: Diagnosis of osteoporosis and assessment of fracture risk. Lancet, 2002, 359 , 1929–1936. Kanis J. A. Diagnosis
Kanis, J. A., McCloskey, E. V., Johansson, H., et al., on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the
cortecosteroid-induced osteoporosis [ Reumatológiai és Fizioterápiás Szakmai Kollégium: NEFMI szakmai protokoll a korral járó és a kortikoszteroidok indukálta osteoporosis diagnosztikájáról és terápiájáról
125 661 669 Kanis, J. A., Johnell, O.: Foundation Requirements for DXA for the management of osteoporosis in Europe. Osteoporos. Int
Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013; 24: 1161–1168. 8 Lin SM, Yang SH, Liang CC, et al. Proton pump inhibitor use and the risk of osteoporosis and
.] 2 Lewiecki EM, Kendler DL, Davison KS, et al. Western osteoporosis alliance clinical practice series: treat-to-target for osteoporosis. Am J Med. 2019; 132: e771–e777
Poór Gy.: Osteoporosis és más metabolikus csontbetegségek a klinikai gyakorlatban. Medicina Kiadó Zrt., Budapest, 2010. Poór Gy. Osteoporosis és más
reported that psoralidin also has multiple pharmacological activities such as anti-tumor [ 2 – 7 ], anti-osteoporosis [ 8 – 12 ] and enhancement of immunity [ 13 – 15 ]. Studies have shown that psoralidin can release a large amount of Ca 2+ in the
